Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma
4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures
4.3 Market Restraints
4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma
4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma
5.1.2 Classic (Mediterranean) Kaposi sarcoma
5.1.3 Endemic (African) Kaposi sarcoma
5.1.4 Latrogenic (transplant-related) Kaposi sarcoma
5.2 By Product
5.2.1 By Diagnostics
5.2.1.1 Biopsy
5.2.1.2 Bronchoscopy
5.2.1.3 Gastrointestinal endoscopy
5.2.1.4 Others
5.2.2 By Treatment
5.2.2.1 Highly Active Antiretroviral Therapy (HAART)
5.2.2.2 Radiation Therapy
5.2.2.3 Chemotherapy
5.2.2.4 Immunotherapy
5.2.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc.
6.1.2 Celgene Corporation
6.1.3 Eli Lilly and Company
6.1.4 Navidea Biopharmaceuticals, Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Bristol-Myers Squibb
6.1.7 Pfizer Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS